Thrombolysis via catheter in treatment of Pulmonary Emboli

Catheter directed thrombolysis versus anticoagulation only in patients with Intermediate-high risk pulmonary emboli-A randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181022041406N1

Enrollment

288

Registered

2019-01-27

Start date

2018-12-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary emboli. Pulmonary embolism

Interventions

Intervention 1: Intervention group: The group will receive catheter directed thrombolysis. After femoral vein puncture, an infusion catheter will be inserted to the diseased pulmonary artery and throm

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women = 18 year-old Acute pulmonary emboli must be confirmed with pulmonary CT angiography Symptoms onset = 14 days Elevated pro b-type natriuretic peptide and cardiac troponin Right ventricle/left ventricle ratio in pulmonary CT angiography >0.9 simplified pulmonary embolism severity index score >=1 Less than 48 hours of anticoagulation therapy

Exclusion criteria

Exclusion criteria: Pulmonary emboli diagnosed with other modalities than pulmonary CT angiography High risk (massive) pulmonary Emboli Segmental pulmonary emboli Patient with terminal illness Surgery within 2 weeks Severe renal dysfunction (creatinine clearance [CrCl] below 30 mL/min) Platelet count <50.000 Thrombolytic contraindication Concomitant right heart thrombosis Pre and post catheter directed thrombolysis echocardiography exam not possible

Design outcomes

Primary

Measure	Time frame
Right ventricular diameter/left ventricular diameter ratio. Timepoint: 3-month after intervention. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Mortality. Timepoint: During hospitalization and 3-months after intervention. Method of measurement: Questionnaire.;Minor bleeding. Timepoint: Duration of hospitalization. Method of measurement: Bleeding Academic Research Consortium scale.;Major bleeding. Timepoint: Duration of hospitalization. Method of measurement: Bleeding Academic Research Consortium scale.;Right ventricular diameter/left ventricular diameter ratio. Timepoint: 72 hours after intervention. Method of measurement: Echocardiography.;Right ventricular recovery. Timepoint: 3 months after intervention. Method of measurement: Echocardiography.	—

Measure

Time frame

Mortality. Timepoint: During hospitalization and 3-months after intervention. Method of measurement: Questionnaire.;Minor bleeding. Timepoint: Duration of hospitalization. Method of measurement: Bleeding Academic Research Consortium scale.;Major bleeding. Timepoint: Duration of hospitalization. Method of measurement: Bleeding Academic Research Consortium scale.;Right ventricular diameter/left ventricular diameter ratio. Timepoint: 72 hours after intervention. Method of measurement: Echocardiography.;Right ventricular recovery. Timepoint: 3 months after intervention. Method of measurement: Echocardiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParham Sadeghipour

Rajaie Cardiovascular Medical and Research Center

psadeghipour@rhc.ac.ir+98 21 2392 2092

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026